Brought to you by 
Biogen Idec, Isis pen third antisense drug discovery deal this year
19 Dec 2019
Executive Summary
In their third deal this year, public biotechs Biogen Idec Inc. and Isis Pharmaceuticals Inc. have partnered to discover and develop antisense drug candidates against three undisclosed targets to treat neurological or neuromuscular disorders.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Biogen Idec, Isis pen third antisense drug discovery deal this year
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice